product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
Met (L41G3) Mouse mAb
catalog :
3148
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
L41G3
reactivity :
human
application :
western blot, immunocytochemistry, immunoprecipitation, flow cytometry
more info or order :
Cell Signaling Technology product webpage
citations: 12
Published Application/Species/Sample/DilutionReference
  • western blot; human; fig 5c
Grugan K, Dorn K, Jarantow S, Bushey B, Pardinas J, Laquerre S, et al. Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells. MAbs. 2017;9:114-126 pubmed publisher
  • western blot; human; fig 1
Wang J, Goetsch L, Tucker L, Zhang Q, Gonzalez A, Vaidya K, et al. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC Cancer. 2016;16:105 pubmed publisher
  • immunocytochemistry; human; fig 5
  • western blot; human; fig 1
Santhana Kumar K, Tripolitsioti D, Ma M, Grählert J, Egli K, Fiaschetti G, et al. The Ser/Thr kinase MAP4K4 drives c-Met-induced motility and invasiveness in a cell-based model of SHH medulloblastoma. Springerplus. 2015;4:19 pubmed publisher
  • western blot; human
Elliott V, Rychahou P, Zaytseva Y, Evers B. Activation of c-Met and upregulation of CD44 expression are associated with the metastatic phenotype in the colorectal cancer liver metastasis model. PLoS ONE. 2014;9:e97432 pubmed publisher
Laviolette L, Mermoud J, Calvo I, Olson N, Boukhali M, Steinlein O, et al. Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein. Nat Commun. 2017;8:15866 pubmed publisher
Ding L, Zhang Z, Liang G, Yao Z, Wu H, Wang B, et al. SAHA triggered MET activation contributes to SAHA tolerance in solid cancer cells. Cancer Lett. 2015;356:828-36 pubmed publisher
Koeppen H, Yu W, Zha J, Pandita A, Penuel E, Rangell L, et al. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin Cancer Res. 2014;20:4488-98 pubmed publisher
Diaz D, Ford K, Hartley D, Harstad E, Cain G, Achilles Poon K, et al. Pharmacokinetic drivers of toxicity for basic molecules: strategy to lower pKa results in decreased tissue exposure and toxicity for a small molecule Met inhibitor. Toxicol Appl Pharmacol. 2013;266:86-94 pubmed publisher
Kentsis A, Reed C, Rice K, Sanda T, Rodig S, Tholouli E, et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med. 2012;18:1118-22 pubmed publisher
Ancot F, Leroy C, Muharram G, Lefebvre J, Vicogne J, Lemiere A, et al. Shedding-generated Met receptor fragments can be routed to either the proteasomal or the lysosomal degradation pathway. Traffic. 2012;13:1261-72 pubmed publisher
Zaytseva Y, Rychahou P, Gulhati P, Elliott V, Mustain W, O CONNOR K, et al. Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. Cancer Res. 2012;72:1504-17 pubmed publisher
Chaudhuri A, Xie M, Yang B, Mahapatra K, Liu J, Marsters S, et al. Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal transduction by the related receptor tyrosine kinases RON and MET. J Biol Chem. 2011;286:32762-74 pubmed publisher
product information
SKU :
3148S
Product-Name :
Met (L41G3) Mouse mAb
Size :
100 ul
Price-(USD) :
235 USD
Species-x-Reactivity :
H, Mk
Applications :
Immunoprecipitation
Product-Category :
RTK
Shipping-Temp :
AMBIENT
Storage-Temp :
-20°C
Product-Type :
Monoclonal Antibody
MW :
145
Host :
Mouse
Target :
Met
Primary-Protein :
Met
Alt-Names :
AUTS9,HGF receptor,HGF/SF receptor,HGFR,Hepatocyte growth factor receptor,MET,Proto-oncogene c-Met,RCCP2,SF receptor,Scatter factor receptor,Tyrosine-protein kinase Met,c-Met,met proto-oncogene (hepatocyte growth factor receptor),met proto-oncogene tyrosine kinase,oncogene MET
more info or order :
Cell Signaling Technology product webpage
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.